Mostrar el registro sencillo del ítem
Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
dc.contributor.author | Rodríguez Sevilla, Juan José | |
dc.contributor.author | Sáinz Pérez, Juan | |
dc.date.accessioned | 2023-06-22T07:51:01Z | |
dc.date.available | 2023-06-22T07:51:01Z | |
dc.date.issued | 2023-04-26 | |
dc.identifier.citation | Rodríguez-Sevilla, J. J., Fernández-Rodríguez, C., Bento, L., Diez-Feijóo, R., Pinzón, S., Gibert, J., ... & Salar, A. (2023). Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. Blood Advances, 7(8), 1606-1614[https://doi.org/10.1182/bloodadvances.2022007949] | es_ES |
dc.identifier.uri | https://hdl.handle.net/10481/82708 | |
dc.description.abstract | Several clinical risk models have been proposed to predict the outcome of follicular lymphoma (FL). The development of next-generation sequencing technologies has allowed the integration of somatic gene mutations into clinical scores to build genotyped-based risk models, such as the m7–Follicular Lymphoma International Prognostic Index (FLIPI). We explored 4 clinical or clinicogenetic-risk models in patients with symptomatic FL who received frontline immunochemotherapy. Of 191 patients with FL grades 1 to 3a, 109 were successfully genotyped. The treatment consisted of rituximab (R) plus cyclophosphamide, vincristine, and prednisone (R-CVP)/cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (72.5%) or R-bendamustine (R-B) (27.5%). The proportion of cases classified as high risk for FLIPI, FLIPI-2, PRIMA–prognostic index, or m7-FLIPI were 39.3%, 14%, 30.3%, and 22%, respectively. No case with low-intermediate FLIPI was upgraded in the m7-FLIPI, but 18 of the 42 high-risk patients with FLIPI were downgraded to low-risk m7-FLIPI. The sensitivity and specificity for the prediction of POD24 were highest for FLIPI. The discrimination between progression-free survival (PFS) and overall survival (OS) was the best for FLIPI (c-index: 0.644 and 0.727, respectively). When analyzed only in patients treated with R-B, m7-FLIPI showed a higher discrimination between PFS and OS. Thus, the FLIPI remains the clinical risk score with higher discrimination in patients with advanced FL treated with immunochemotherapy; however, the performance of the m7-FLIPI should be further investigated in patients treated with R-B. | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III (ISCIII | es_ES |
dc.description.sponsorship | European Union (FIS-FEDER PI15/0459, FIS-FEDER PI19/00034 | es_ES |
dc.description.sponsorship | GILEAD GLD18/00117, 2017SGR205, and PT20/00023) | es_ES |
dc.description.sponsorship | Xarxa de Banc de Tumors de Catalunya | es_ES |
dc.description.sponsorship | Pla Director d’Oncologia de Catalunya | es_ES |
dc.description.sponsorship | The biobank of the Fundación | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Society of Hematology | es_ES |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.1182/bloodadvances.2022007949 | |
dc.type.hasVersion | VoR | es_ES |